In 2008, Denmark started to offer free vaccination against human papillomavirus (HPV) with the 4-valent HPV vaccine to teenage girls around the age of 14. New data from a cohort study presenting results from the national cervical screening programme among young women who were vaccinated as girls, show that infection with HPV types covered by the vaccine has been almost eliminated.

New research in JNCCN finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated according to NCCN Guidelines, 90% were likely to survive their cancer for their remaining life-expectancy.

Metastasis researcher Dr. Joan Massagué shares four emerging insights into how cancer spreads.

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the first-line treatment for people with advanced biliary tract cancer (aBTC), researchers have shown that after three years more than twice as many study participants treated with durvalumab plus GemCis had survived compared to those treated with a placebo plus GemCis. The new results in the Journal of Hepatology, published by Elsevier, establish a new survival benchmark for people living with aBTC and reinforce durvalumab plus GemCis as a standard of care for first-line treatment for aBTC.

CZI announced its latest AI model, GREmLN, aimed at helping researchers better understand how cells behave by focusing on the key networks that control cell behavior.

 Researchers from The University of Osaka have identified key genetic mutations linked to extracranial arteriovenous malformations (AVMs), a rare and potentially serious vascular disorder. They have revealed that these mutations activate the RAS/RAF/MEK signaling pathway and that the MAP4K4 gene may drive pathological angiogenesis. This may mean that existing cancer drugs that target the same pathway could be effective for AVM treatment, potentially paving the way for novel therapies.